Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Itraconazole on Surufatinib Pharmacokinetics in Healthy Subjects
NCT04372407Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of surufatinib in neuroendocrine tumors (NETs), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration, Area under the plasma concentration-time curve and 1 more. Started Jul 2020; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04372407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372407.